Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

NCT06772168 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia
Type 2 Diabetes

Interventions

DRUG: CMG190303(Dapagliflozin/Rosuvastatin)
DRUG: Comparator 1: Dapagliflozin/Rosuvastatin placebo
DRUG: Rosuvastatin/Dapagliflozin placebo

Sponsor

CMG Pharmaceutical Co. Ltd